US Stocks Move: Nektar Therapeutics rises another 3% pre-market as alopecia areata drug trial meets expected results

Glonghui, April 21 ― A certain exchange continued to rise 3.53% in pre-market trading for U.S. stocks today, closing at $103.89. Yesterday, the stock saw a large gain of 18.25% to close at $100.35, up 1.37 times year-to-date.On the news side, on April 20, the exchange announced top-line results from the 52-week extension of the phase 2b REZOLVE-AA study of its alopecia areata treatment drug, rezpegaldesleukin, after a 16-week extension. Data showed that in the 18 µg/kg and 24 µg/kg dose groups, 29% and 31% of patients, respectively, achieved a new SALT score ≤20 from week 36 to week 52, and 94% of patients completed treatment extension with clinically meaningful hair regrowth.After the release of the long-term extension results of the alopecia study, Oppenheimer reiterated its “Outperform” rating and $140 target price for the exchange, stating that the overall SALT ≤20 response rate in the 24 µg/kg dose group at week 52 was about 28%, in line with its best expected range.